Brokers Set Expectations for Opus Genetics Q1 Earnings

Opus Genetics, Inc. (NASDAQ:IRD) – Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Opus Genetics in a research report issued on Tuesday, April 1st. HC Wainwright analyst M. Caufield anticipates that the company will post earnings per share of ($0.34) for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 target price on the stock. The consensus estimate for Opus Genetics’ current full-year earnings is ($1.22) per share. HC Wainwright also issued estimates for Opus Genetics’ Q2 2025 earnings at ($0.26) EPS, Q3 2025 earnings at ($0.26) EPS, Q4 2025 earnings at ($0.24) EPS and FY2029 earnings at $0.00 EPS.

Separately, Jones Trading dropped their target price on shares of Opus Genetics from $9.00 to $8.00 and set a “buy” rating for the company in a research report on Tuesday.

Opus Genetics Stock Up 2.5 %

IRD opened at $0.93 on Wednesday. Opus Genetics has a 12 month low of $0.81 and a 12 month high of $1.56. The company has a 50-day simple moving average of $1.07. The stock has a market cap of $29.89 million, a PE ratio of -0.86 and a beta of 0.28.

Opus Genetics (NASDAQ:IRD) last announced its earnings results on Monday, March 31st. The company reported ($1.27) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.93). The firm had revenue of $3.40 million during the quarter, compared to analyst estimates of $11.10 million. Opus Genetics had a negative net margin of 324.45% and a negative return on equity of 63.65%.

About Opus Genetics

Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc, formerly known as Ocuphire Pharma Inc, is based in Farmington Hills, Michigan.